Company intelligence / Profile preview

OxyNov

Quebec City, Quebec, Canada

Ownership: Private
Employees: ~25
Development stage: Other

Overview

OxyNov has commercialized the FreeO2 device, an automated oxygen therapy device that continuously adjusts oxygen flow based on target saturations using a closed-loop system. The device has been in business in Europe since 2017 and in Canada since 2019, with FDA 510(k) submission filed in September 2022 for U.S. market entry.

Therapeutic areas: CardiovascularPulmonology
Modalities: Device
Industry: Therapeutic Medical Devices

Beyond the preview

Go deeper on OxyNov.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on OxyNov.

Explore the full profile